MARKET

MTVA

MTVA

MetaVia Inc
NASDAQ
0.6500
-0.0507
-7.24%
After Hours: 0.6780 +0.028 +4.31% 16:18 05/13 EDT
OPEN
0.6900
PREV CLOSE
0.7007
HIGH
0.7055
LOW
0.6500
VOLUME
227.94K
TURNOVER
--
52 WEEK HIGH
5.30
52 WEEK LOW
0.6470
MARKET CAP
6.56M
P/E (TTM)
-0.1827
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MTVA last week (0505-0509)?
Weekly Report · 1d ago
MetaVia launches $10M private placement
Seeking Alpha · 4d ago
MetaVia announces $10 million private placement
Seeking Alpha · 4d ago
MetaVia announces $10M private placement
TipRanks · 4d ago
METAVIA INC - PROCEEDS TO FUND DA-1726 CLINICAL DEVELOPMENT FOR OBESITY
Reuters · 4d ago
MetaVia announces data from DA-1241 trial at EASL
TipRanks · 6d ago
MetaVia Presents Phase 2a Data at EASL 2025 Showing DA-1241, A GPR119 Agonist, Significantly Lowers ALT And Liver Fat An Presumed MASH Patients
Benzinga · 6d ago
Weekly Report: what happened at MTVA last week (0428-0502)?
Weekly Report · 05/05 10:27
More
About MTVA
More
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Recently
Symbol
Price
%Change

Webull offers MetaVia Inc stock information, including NASDAQ: MTVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTVA stock methods without spending real money on the virtual paper trading platform.